Facebook
Twitter
Telegram
Report an ErrorDenali Therapeutics Financial Ratios 2011-2024 | DNLI
Annual Financial Ratios Denali Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-10.3 | -13.6 | 110.0 | -11.3 | -48.3 | -4.0 | - | - | - | - | - | - |
P/S |
31.0 | 81.3 | 23.3 | 83.4 | 13.6 | - | - | - | - | - | - | - |
EPS |
-2.6 | -2.4 | 0.7 | -2.1 | -0.4 | -5.9 | -13.5 | - | - | - | - | - |
EV (Enterprise Value) |
3.56 B | 4.11 B | 7.77 B | 2.3 B | 1.79 B | 157 M | -23.8 M | 52.3 M | - | - | - | - |
EBITDA per Share |
-2.63 | -2.36 | 0.65 | -2.15 | -0.421 | -5.82 | - | - | - | - | - | - |
EV/EBITDA |
-14.1 | 84.8 | -10.5 | -43.0 | -1.6 | - | - | - | - | - | - | |
PEG |
- | 0.68 | 0.03 | -0.52 | 0.02 | - | - | - | - | - | - | |
P/B |
3.2 | 4.1 | 6.8 | 5.6 | 3.2 | 0.8 | - | - | - | - | - | - |
P/CF |
-13.7 | -18.7 | 18.8 | -13.1 | 37.5 | -4.5 | - | - | - | - | - | - |
ROE % |
-31.27 | -30.20 | 6.18 | -50.04 | -6.63 | -18.93 | - | - | - | - | - | - |
ROA % |
-22.32 | -20.69 | 4.43 | -35.72 | -5.47 | -18.12 | - | - | - | - | - | - |
ROCE % |
-32.69 | -30.73 | 5.45 | -41.97 | -7.37 | -19.07 | - | - | - | - | - | - |
Current Ratio |
3.5 | 3.2 | 3.5 | 9.5 | 14.7 | 28.9 | - | - | - | - | - | - |
DSO |
- | - | - | - | 24.2 | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Denali Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.72 | 1.34 | -0.8 | - | -0.84 | -0.48 | -0.53 | - | -0.69 | -0.5 | -0.58 | - | -0.54 | -0.56 | -0.55 | -0.56 | -0.48 | -0.61 | -0.41 | 0.82 | -0.38 | -0.59 | -0.26 | -0.74 | -2.14 | -2.29 | -2.36 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
- | - | -0.81 | - | -0.82 | -0.47 | -0.53 | - | -0.65 | -0.47 | -0.57 | - | -0.5 | -0.54 | -0.56 | -0.6 | -0.46 | -0.61 | -0.42 | 0.79 | -0.35 | -0.59 | -0.28 | -0.27 | -1.96 | -2.18 | -2.33 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-17.52 | -21.37 | -43.47 | -26.49 | -34.84 | -30.47 | -29.48 | -20.35 | -25.41 | -22.12 | -21.57 | -15.10 | -28.78 | -35.44 | -45.10 | -50.04 | -22.18 | -16.94 | -12.17 | -6.63 | -25.72 | -23.94 | -18.68 | -18.93 | -14.02 | -9.33 | -4.58 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-10.19 | -10.57 | -29.17 | -17.90 | -23.74 | -21.15 | -20.63 | -14.38 | -18.01 | -15.80 | -15.45 | -10.83 | -20.60 | -25.33 | -32.21 | -35.72 | -14.24 | -11.22 | -8.95 | -5.47 | -21.89 | -21.03 | -17.31 | -18.12 | -13.42 | -8.93 | -4.38 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-21.56 | -24.63 | -45.94 | -27.44 | -35.89 | -31.10 | -29.92 | -20.66 | -25.89 | -22.66 | -22.22 | -15.76 | -30.39 | -37.87 | -48.43 | -53.99 | -25.70 | -19.94 | -14.54 | -8.48 | -27.20 | -25.04 | -19.39 | -19.35 | -14.30 | -9.51 | -4.67 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
10.4 | 11.0 | 3.2 | 3.5 | 3.0 | 3.2 | 3.3 | 3.2 | 3.3 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 5.8 | 5.8 | 5.8 | 5.8 | 23.3 | 23.3 | 23.3 | 23.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | 131.4 | 30.3 | 49.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | 131.4 | 30.3 | 49.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | 131.4 | 30.3 | 49.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency